Founded by Dr. Peter E. Lipsky and Dr. Amrie C. Grammer, AMPEL BioSolutions R&D program is focused on using big data tools for improving health care. We began in 2013 by developing a multi-pronged approach to rank existing drugs in the marketplace to be repositioned for the safe, effective treatment of lupus. As a result, we can identify drugs that should be considered top priorities for treating lupus patients and our system can be applied to any disease. Last fall, AMPEL’s system for drug repositioning was confirmed by the success of the phase II trial of Stelara [an immunosuppressive drug] in lupus, meaning for the first time in 60 years, lupus patients have a new treatment option. And this spring we announced a breakthrough in precision medicine for the treatment of lupus patients. Until now, rheumatologists have not had a tool that predicts when a lupus patient is about to experience a flare-up. AMPEL’s approach to personalized medicine identifies the groups of genes expressed in the blood of lupus patients in real time, assesses if the patient is flaring and provides decision support to physicians for top drugs that could be prescribed to precisely treat that patient. In addition, our approach supports clinical trial enrollment for testing new drugs by ensuring that patients entered into a trial actually have the potential to respond to the drug tested, which is not always the case in clinical trials, and the reason so many trials fail. AMPEL also has patented tools and machine-learning approaches for a clinical genomic test that can predict top drug options for a patient based on individual gene expression. Our work really demonstrates the importance and powerful role that data science is playing in drug discovery and personalized medicine.